A defence of the small clinical trial: evaluation of three gastroenterological studies.

Emphasis has been placed on the importance of ?, the type II error, in clinical trials and the corresponding necessity of including large numbers of subjects in a study.1 Large trials are in fashion and small trials?even when they yield statistically significant results?are regarded with suspicion; a small trial which does not show a conventional statistically significant difference is often thought worthless. Interpretation of the small trial has increasingly been recognised to be dangerous, and the argument that lack of a significant difference between two treatments must mean that they have equal efficacy is recognised to be false. The need for large trials is undeniable in diseases such as cancer and cardiovascular prob? lems where earlier trials have excluded large advantages for new treatments and small differences in outcome are still clinically and socially important. The unfortunate consequence of the emphasis on large trials in these settings is that small trials conducted in other diseases where only large differences in outcome are relevant have illogically become unacceptable in many people's minds. With appropriate statistical analysis, including calculation of the confidence limits for the likely "true" difference, small controlled trials can provide clinically useful information. We present three such small clinical trials?none of which show conventional

[1]  T C Chalmers,et al.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.

[2]  B. W. Brown,et al.  Statistical controversies in the design of clinical trials—Some personal views* , 1980 .

[3]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[4]  Betamethasone 17-Valerate and Prednisolone 21-Phosphate Retention Enemata in Proctocolitis: A MULTICENTRE TRIAL , 1971, British medical journal.

[5]  W. Grove Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[6]  F. H. Tyler,et al.  DIURNAL VARIATION IN SUPPRESSION OF ADRENAL FUNCTION BY GLUCOCORTICOIDS. , 1965, The Journal of clinical endocrinology and metabolism.

[7]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[8]  G. Labó,et al.  TREATMENT OF ULCERATIVE COLITIS WITH HIGH-DOSE 5-AMINOSALICYLIC ACID ENEMAS , 1981, The Lancet.

[9]  V. R. Richards,et al.  Nifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal Subjects , 1983, Journal of clinical pharmacology.

[10]  R. G. Leonard,et al.  Calcium-channel blocking agents. , 1982, Clinical pharmacy.

[11]  J. Lennard-jones,et al.  Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis. , 1976, British medical journal.

[12]  J. Lellouch,et al.  EXPLANATORY AND PRAGMATIC ATTITUDES IN THERAPEUTICAL TRIALS , 2003 .

[13]  R. Heading,et al.  Effect of nifedipine on oesophageal motility and gastric emptying. , 1981, Digestion.

[14]  J. Lennard-jones,et al.  Sensibility of the rectum to distension and the anorectal distension reflex in ulcerative colitis. , 1978, Gut.

[15]  J. Fleiss Statistical methods for rates and proportions , 1974 .

[16]  P. Bacon,et al.  Single daily dose corticosteroid treatment. Effect on adrenal function and therapeutic efficacy in various diseases. , 1971, Annals of the rheumatic diseases.

[17]  M. Bortolotti,et al.  Clinical and manometric effects of nifedipine in patients with esophageal achalasia. , 1981, Gastroenterology.

[18]  F. Jones,et al.  Comparison of Oral and Rectal Steroids in the Treatment of Proctocolitis , 1964, Proceedings of the Royal Society of Medicine.

[19]  I. Calder,et al.  Nephrotoxic Lesions from 5-Aminosalicylic Acid , 1972, British medical journal.